A health economic guide to market access of biosimilars by Simoens, S. (Steven) & Vulto, A.G. (Arnold)
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=iebt20
Expert Opinion on Biological Therapy
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/iebt20
A health economic guide to market access of
biosimilars
Steven Simoens & Arnold G. Vulto
To cite this article: Steven Simoens & Arnold G. Vulto (2021) A health economic guide
to market access of biosimilars, Expert Opinion on Biological Therapy, 21:1, 9-17, DOI:
10.1080/14712598.2021.1849132
To link to this article:  https://doi.org/10.1080/14712598.2021.1849132
© 2020 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 05 Jan 2021.
Submit your article to this journal 
Article views: 82
View related articles 
View Crossmark data
PERSPECTIVE
A health economic guide to market access of biosimilars
Steven Simoensa and Arnold G. Vulto a,b
aDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium; bHospital Pharmacy, Erasmus University Medical 
Center, Rotterdam, The Netherlands
ABSTRACT
Introduction: Little is known about market access to biosimilars from a health economic perspective, 
except for studies that compute the budget impact of biosimilar use.
Areas covered: This comprehensive health economic guide to the market access of biosimilars focuses 
on the role of biosimilars in pharmaceutical innovation and competition, the objective of biopharma-
ceutical policy, the budget impact of biosimilars, and the cost-effectiveness of biologic therapy in the 
presence of biosimilars.
Expert opinion: We argue that the objective of biopharmaceutical policy in a health system should be 
to create a competitive and sustainable market for off-patent reference biologics, biosimilars, and next- 
generation biologics that makes biologic therapy available to patients at the lowest cost. Market access 
of biosimilars can contribute to this objective as a result of the lower price of biosimilars and price 
competition with alternative therapies. The resulting improvement in the cost-effectiveness of biologic 
therapy needs to be accounted for by revisiting reimbursement decisions and conditions. When 
examining the cost-effectiveness of biologic therapy following patent expiry, stakeholders need to 
consider residual uncertainties at the time of biosimilar marketing authorization, the nocebo effect, 
market entry of a second-generation reference biologic with a different administration form than the 
biosimilar, and value-added services.
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There is room to improve patient access to biologic therapy. 
For instance, a multinational survey in Europe and Canada 
found that 19–24% of the dermatologists considered costs to 
present a hurdle to access biologic therapy in psoriasis [1]. 
Another survey showed that infliximab, etanercept, adalimu-
mab, certolizumab pegol, golimumab, abatacept, tocilizumab, 
and rituximab were not reimbursed for rheumatoid arthritis in 
22% of the European countries and that the cost of annual 
treatment with biologic therapy surpassed gross domestic 
product per capita in 57% of these countries [2]. Given that 
costs are one factor influencing access, the market entry of 
biosimilars, medicines which exhibit similar efficacy at 
a reduced price as the reference biologic and which can be 
launched following the expiry of patent and exclusivities of 
the reference biologic, is instrumental in supporting patient 
access to biologic therapy.
To date, market access of biosimilars has received little 
attention in the health economic literature, except for studies 
that have simulated or calculated the savings generated by 
using biosimilars instead of reference biologics [3]. The aim of 
this Expert Opinion article is to provide a comprehensive 
health economic guide to the market access of biosimilars. 
For this purpose, the article discusses: a) the role of biosimilars 
in pharmaceutical innovation and competition; b) the objec-
tive of biopharmaceutical policy; c) the budget impact of  
biosimilars; d) the impact of biosimilar entry on the cost- 
effectiveness and reimbursement of biologic therapy; and e) 
the factors affecting the cost-effectiveness of biologic therapy 
following patent expiry. This guide will help decision and 
policymakers to optimize the use of biosimilars in a market 
environment consisting of off-patent reference biologics, bio-
similars, and new innovative chemical and biologic medicines.
We illustrate our arguments by drawing on published evi-
dence related to Europe (and with a few additional examples 
from other countries). This geographical focus is chosen because 
there is more extensive experience with biosimilars in Europe 
than in less mature markets such as the United States (although 
the number of biosimilars entering the market in the United 
States is in line with that in Europe since 2017) or Canada [4]. 
Also, marketing authorization frameworks, pricing and reimbur-
sement regulation, and biosimilar policies vary between coun-
tries [5,6]. Examples relate to a variety of products given that 
market dynamics differ between classes of biosimilars (and bio-
logics) depending on, for example, product features, observabil-
ity of effect, duration of clinical experience, and use in supportive 
or therapeutic care [7].
This Expert Opinion article is based on a scoping review, 
a method particularly suited to provide an overview of 
a recent area of research such as health economic aspects of 
market access of biosimilars. The literature search encom-
passed the peer-reviewed literature (PubMed and relevant 
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journals not indexed in PubMed such as the Generics and 
Biosimilars Initiative Journal) and the gray literature (abstracts 
of International Society for Pharmacoeconomics and 
Outcomes Research (ISPOR) conferences, consultancy reports, 
policy documents, government agency, and company web-
sites). The search terms included ‘reference biologic,’ ‘biosi-
milar,’ ‘next-generation biologic,’ ‘off-patent,’ ‘budget impact,’ 
‘savings,’ ‘affordability,’ ‘cost-effectiveness,’ ‘economic evalua-
tion,’ ‘health technology assessment,’ ‘reimbursement,’ ‘com-
petition,’ ‘innovation,’ ‘pharmaceutical policy,’ ‘substitution,’ 
‘switch,’ ‘tender,’ and ‘gainsharing.’ The bibliography of the 
included articles was searched for relevant references.
2. Competition versus innovation
It is often argued that biosimilar competition provides 
a disincentive for manufacturers to invest in research and 
development of new biologic therapies, i.e. market entry of 
biosimilars may threaten the economic viability of reference 
biologics as a result of possible price competition. On the 
other hand, it can also be argued that manufacturers may 
safeguard their economic viability by focusing on the devel-
opment of new biologic therapies for which there is no biosi-
milar competition as long as patents and exclusivities have not 
expired. This can be illustrated by two examples. First, of the 
14 manufacturers that had biosimilars in their portfolio out of 
the worldwide top 25 manufacturers based on prescription 
drug sales in 2015, all but one also developed reference 
biologics [8]. Second, following the patent expiry of Humira® 
(adalimumab, AbbVie), the world’s best-selling medicine, and 
the market entry of adalimumab biosimilars, AbbVie chose to 
invest in the research and development of new biologic and 
chemical therapies (like JAK-inhibitors) [9].
Little research has been conducted on how biosimilars may 
have an influence on the dynamics of competition and inno-
vation in the pharmaceutical sector from an industrial eco-
nomic perspective. In this respect, for instance, a European 
study suggested that the market presence of at least two 
biosimilar manufacturers induce competition [10]. Using 
a theoretical model, a US study explored biosimilar market 
access and price evolution in the off-patent biologic mar-
ket [11].
3. Biopharmaceutical policy and biosimilars
We believe that biopharmaceutical policy should aim to create 
a competitive and sustainable market for off-patent reference 
biologics, biosimilars, and next-generation biologics with 
a view to making biologic therapy available to patients at 
the lowest cost, rather than to promote biosimilar uptake. 
This serves to maximize savings from lower-priced biosimilars 
and from price competition with other biologics. Hence, the 
relevant outcome measure is the evolution in the average cost 
of biologic therapy over time instead of biosimilar market 
share. For instance, the observation that hospital expenditure 
(net of discounts) per patient fell by 44% for etanercept and 
by 50% for infliximab between 2014 and 2018 in the 
Netherlands is, in our opinion, a key indicator of a successful 
biosimilar policy [12]. Focusing on the class of erythropoiesis- 
stimulating agents (including off-patent reference biologics, 
biosimilars, and next-generation biologics), the volume- 
weighted average ex-manufacturer price per defined daily 
dose had fallen by 27% in European Union countries in 2018 
as compared to the year before the first biosimilar epoetin 
product entered the market [4].
However, limited data are available about the evolution in 
the cost of biologic therapy over its life cycle. The Swedish 
Dental and Pharmaceutical Benefits Agency publishes 
each year a price comparison of outpatient medicines in 20 
European countries in the years after market approval, which 
gives an idea of how costs change following patent expiry, 
taking into account the caveats that data relate to list prices 
and are not limited to biologic medicines [13].
Examples of biopharmaceutical policies that focus on mak-
ing biologic therapy available to patients at the lowest cost 
are found in a number of European countries (see Table 1). 
Although the objective of biopharmaceutical policy should 
not be to promote biosimilar uptake as such, we acknowledge 
that a minimum biosimilar market share is likely to be one of 
the factors required to create a competitive market environ-
ment for biologic therapy. Policies affecting biosimilar uptake 
have been discussed elsewhere [14–17].
4. Budget impact of biosimilars
Due to their lower price, biosimilars provide savings to the 
pharmaceutical budget and support the sustainability of the 
health-care system. For instance, price comparison in EU coun-
tries showed that rituximab biosimilars were 39% less expen-
sive than reference rituximab at the manufacturer level and 
Article highlights
● The objective of biopharmaceutical policy should be to create 
a competitive and sustainable market comprising off-patent refer-
ence biologics, biosimilars, and next-generation biologics that makes 
biologic therapy available to patients at the lowest cost.
● The cost of biologic therapy can be reduced by the market access of 
biosimilars and by price competition with alternative treatments.
● Budget impact analyses need to consider all relevant market 
dynamics, including the evolution in disease epidemiology, the initia-
tion of biologic-naïve patients on biosimilar and switching practices 
for patients treated with a biologic, price competition with alterna-
tive therapies, and the market entry of new innovative chemical or 
biologic medicines.
● The improvement in the cost-effectiveness of biologic therapy in the 
presence of biosimilars needs to be accounted for by revisiting 
reimbursement decisions and conditions.
● When examining the cost-effectiveness of biologic therapy following 
patent expiry, stakeholders need to consider residual uncertainties at 
the time of biosimilar marketing authorization, the nocebo effect, 
market entry of a second-generation reference biologic with 
a different administration form than the biosimilar, and value- 
added services.
This box summarizes the key points contained in the article.
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86% cheaper at the retail level [23]. The lower price of biosi-
milars arises from reduced costs of researching, developing, 
and marketing biosimilars: R&D costs of a biosimilar have been 
estimated to amount to 100 USD – 300 USD million (as com-
pared to 2.6 USD billion for an innovative medicine, including 
the cost of failures) [4,24,25].
In addition to the lower price of biosimilars, market entry of 
these products may induce competition and, thus, reduce the 
price of the reference biologic. A budget impact analysis 
quantified the relative contribution of biosimilar uptake and 
price competition to the overall savings of €153 million arising 
from the launch of rituximab biosimilars in Italy over 5 years 
[26]. This study found that price competition was the domi-
nant driver and accounted for 67% of the savings. In the 
United Kingdom, the uptake of biosimilar infliximab generated 
65% of the savings and price competition made up 35% of the 
savings from March 2015 until February 2017 [27]. Instead of 
relying on price competition, some countries regulate prices 
following biosimilar market entry: for example, the price of the 
reference biologic is required to drop (at least) to the level of 
the biosimilar price in Spain, although price competition can 
lead to further price reductions [28].
IQVIA used a modeling exercise to estimate biologic spend-
ing and savings from biosimilar competition as a proportion of 
total prescription medicine spending in 2019 [4]. In the case of 
Germany, where prices in the retail market are established 
through rebate contracts between health insurance funds 
and manufacturers, biologics accounted for 11% of the total 
prescription medicine spending, savings in list prices from 
actual biosimilar competition amounted to 2%, and additional 
savings of 6% could be attained if biosimilar competition is 
fully leveraged.
Savings arising from biosimilar uptake and price competi-
tion depend on, for example, the procurement mechanism. 
Tendering is such a mechanism, which is widespread across 
Europe, although the specific features tend to differ between 
countries [29]. Table 2 describes tender mechanisms in various 
countries and qualitatively assesses how the design features of 
these tenders influence the competition and sustainability of 
the market, the risk of shortages, and the physician freedom of 
product choice [30]. According to an IQVIA report, single- 
winner tenders at the hospital level may maximize price com-
petition, but they exclude other manufacturers from the mar-
ket, thus increasing supply risks and threatening long-term 
market sustainability [30]. The evidence also indicated that 
multiple-winner tenders may generate the largest savings 
because they attain price decreases on all tendered products 
for all uses/indications. Although the price is a key criterion for 
awarding tenders for biologics, it needs to be noted that 
criteria other than price can be taken into account (see 
Figure 1) [31].
Savings arising from biosimilar competition can be re- 
invested to treat more patients with the same disease or can 
be re-allocated to treat patients suffering from other diseases 
[35]. For instance, a UK study explored whether more health 
Table 1. Examples of policies that aim to make biologic therapy available to 
patients at the lowest cost.
Country Biopharmaceutical policy
Austria When multiple products are on the market, physicians are 
encouraged to prescribe the most cost-effective product [14]
Belgium Policy is geared at promoting the use of a ‘cheap’ biologic 
medicine, be it a biosimilar medicine or the reference biologic 
with a reduced price [18]
Denmark Amgros organizes national tenders for hospital medicines, 
selecting the cheapest product [19]
England NHS England has set targets for the uptake of ‘best-value 
biologics’ in specialized services for both new and applicable 
existing patients [20]
Ireland The Health Service Executive Medicines Management Programme 
identifies ‘best-value biologics’ based on 13 criteria (including 
cost), and Prescribing and Cost Guidance is published to 
support clinicians in prescribing these medicines [21]
Italy If more than three biologic/biosimilar products using the same 
active substance are available, physicians need to prescribe one 
of the three cheapest products as identified in a regional tender 
(law 232/2016)
Slovakia A reference-pricing system groups biologic and biosimilar 
medicines based on the same active substance and 
administration form, and sets the reference price at the level of 
the cheapest product [22]











Belgium Tenders per hospital or hospital group, usually one winner, variable duration [32] + + - - -
Denmark One-year national tender for hospital medicines with only the cheapest product 
being reimbursed [19]
++ –– –– ––
England NHS England has tender design for adalimumab that splits up market in 11 hospital 
groups, provides access to reference product and biosimilar adalimumab, and 
grants market shares to multiple manufacturers depending on their price bids 
[33]
++ ++ ++ ++
Norway One-year national tender per indication with all products being reimbursed and 
ranked based on price, and recommendation to physicians to prescribe cheapest 
product [29]
++ - - -
Poland One-year tenders per hospital with expectation that only the cheapest product is 
reimbursed [29]
+ - - - - -
Sweden Regional tenders for hospital medicines, usually for 2 years (shorter duration when 
new competitors are expected), one winner or multiple winners (with all 
products being reimbursed and recommendation to physicians to prescribe 
cheapest product) [29,34]
+ + + +
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gain could be generated by using biosimilar adalimumab sav-
ings to treat additional patients suffering from rheumatoid 
arthritis or to treat patients with melanoma, hepatitis C, multi-
ple sclerosis, Duchenne’s disease, or non-small cell lung cancer 
[36]. As a result of the better cost-effectiveness of the available 
therapy for hepatitis C, a higher number of quality-adjusted 
life years were gained when biosimilar adalimumab savings 
were spent on treating patients with hepatitis C rather than on 
treating more patients with rheumatoid arthritis.
Savings may also serve to expand access to treatment in for 
example Eastern-European countries within the constraints of 
the same pharmaceutical budget [37]. In the Czech Republic, 
additional 1,000 patients with inflammatory bowel disease 
could be treated with biologic therapy in 2014 (as compared 
to 2013), thanks to savings from biosimilar competition [38]. 
However, this effect was not observed in Hungary following 
the market entry of biosimilar infliximab: most biologic-naïve 
patients who qualified for reimbursement in the indications of 
infliximab were initiated on treatment with other patented 
reference biologics and patients treated with reference inflix-
imab were largely switched to other patented reference bio-
logics [39]. This example emphasizes that the budget impact 
of biosimilars should not be investigated in isolation, but also 
needs to consider shifts in physician prescribing behavior.
It is often argued that savings from biosimilar competition 
provide ‘headroom for innovation’ and allow society to reim-
burse new innovative medicines [35]. As the amount of biosi-
milar savings may not suffice to cover all patients who are 
eligible for the new medicines, the overall pharmaceutical 
budget may actually increase. Nonetheless, we believe that 
such an increase is valuable if these new medicines are cost- 
effective.
Countries such as France, Germany, Norway, and the United 
Kingdom have set up gainsharing arrangements [10], so that 
savings from biosimilar competition flow back to stakeholders 
(such as health-care payers, hospitals, and physicians) and can 
be used to improve patient care. Savings can also cover the 
possible costs involved in non-medical switching, i.e. when 
a patient is switched from a reference biologic to its biosimilar, 
is switched back, or is switched between biosimilars out of an, 
for example, economic rationale [40]. Whether non-medical 
switching from reference biologics to biosimilars is associated 
with costs is not (yet) clear: a recent systematic literature 
review found limited evidence on this topic and pointed to 
methodological limitations of existing studies [41]. 
Nevertheless, NHS Scotland, for example, recommends to 
implement ‘invest to save’ arrangements to pay for managed 
switching programs now with a view to generate savings from 
biosimilar competition later [42].
Finally, budget impact analyses are typically carried out 
over a period of three to 5 years. From a methodological 
perspective, a budget impact analysis of a biosimilar needs 
to consider all relevant market dynamics during that time 
horizon, including the evolution in the epidemiology of the 
disease, the initiation of biologic-naïve patients on 
a biosimilar, and switching practices for patients treated with 
a biologic, price competition with alternative therapies, the 
market entry of new innovative chemical or biologic medi-
cines (see Figure 2). For instance, a study calculated the bud-
get impact of biosimilar infliximab in rheumatology and 
inflammatory bowel disease, taking into account the launch 
of vedolizumab, biosimilar etanercept, and biosimilar rituxi-
mab over the studied period [43]. However, few budget 
impact analyses of biosimilars to date have been able to 
capture the broad market environment in which biosimilars 
are used [3].
5. Economic evaluation of biosimilars
Given that a biosimilar provides similar efficacy and safety at 
a lower price than the reference biologic, biosimilar use 
improves the cost-effectiveness of biologic therapy. This can 
Figure 1. Tender criteria for biologics other than price [31].
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be exemplified by a Canadian economic evaluation that calcu-
lated the cost-effectiveness of cetuximab plus best supportive 
care as compared to best supportive care for metastatic colon 
cancer: the incremental cost-effectiveness ratio was 299,613 
USD per quality-adjusted life-year gained with reference 
cetuximab and 261,126 USD per quality-adjusted life-year 
gained with biosimilar cetuximab [44].
It follows that the cost-effectiveness of biologic therapy can 
change through its lifecycle as a result of, for example, the 
market entry of biosimilars or of new innovative chemical or 
biologic medicines. This also implies that new innovative 
medicines which charge a premium price may struggle to be 
cost-effective and receive reimbursement when the therapeu-
tic arsenal includes biosimilars of an earlier generation of 
biologic therapy [45,46].
The improved cost-effectiveness of biologic therapy due to 
biosimilars may have an influence on reimbursement decision 
and on reimbursement conditions.
First, improved cost-effectiveness may allow to award reim-
bursement: for instance, the English National Institute for Health 
and Care Excellence (NICE) concluded in 2016 that infliximab 
treatment with only the cheapest product is recommended for 
adults suffering from severe active ankylosing spondylitis whose 
disease has not responded adequately to or who do not tolerate 
non-steroidal anti-inflammatory drugs [47].
Second, improved cost-effectiveness may allow to grant 
reimbursement in a sub-population: a US economic evalua-
tion, for example, demonstrated that not only reference bev-
acizumab but also biosimilar bevacizumab (at a hypothetical 
30% price reduction) was not a cost-effective add-on to first- 
line therapy for patients with advanced ovarian cancer [48]. 
However, biosimilar bevacizumab was cost-effective in 
patients with stage IV disease, in ECOG PS 1 patients, and in 
patients at a high risk of disease progression. What price 
reduction of biosimilar bevacizumab will be actually observed 
in the US market depends on a myriad of factors, including 
R&D costs, the extent of competition (and the number of 
biosimilar products entering the market), rebate contracting, 
and the occurrence of industry practices such as patent litiga-
tion activities and ‘pay for delay’ agreements [49].
Third, improved cost-effectiveness may allow to extend 
reimbursement to indications for which the reference biologic 
was not reimbursed: for instance, biosimilar epoetin alfa was 
fully reimbursed for the treatment of anemia, kidney failure, 
and cancer in Slovakia and Croatia in 2016, while reference 
epoetin alfa was not reimbursed for these indications [50]. 
Although reference somatropin is not reimbursed for the indi-
cation of short stature in children born too small for gesta-
tional age in Poland, biosimilar somatropin was awarded 
reimbursement for this indication following an assessment 
by the Agency for Health Technology Assessment and Tariff 
System (AOTMiT) in 2014 [51].
Fourth, improved cost-effectiveness due to biosimilars may 
contribute to the cost-effectiveness (and thus reimbursement) 
of combination treatments involving new innovative biologics. 
NICE, for example, found that the incremental cost- 
effectiveness ratio of the combination treatment consisting 
of pertuzumab, intravenous trastuzumab, and chemotherapy 
for HER2-positive early-stage breast cancer in adults who have 
lymph node-positive disease fell below the threshold value of 
£20,000 per quality-adjusted life-year, if the economic evalua-
tion applied discounted prizes of pertuzumab and biosimilar 
trastuzumab [52].
Fifth, reimbursement conditions may change as a result of 
the improved cost-effectiveness of biologic therapy following 
the market entry of biosimilars, so that biologic therapy is 
reimbursed at an earlier stage of the disease or as an earlier 
treatment line or that physician prescribing restrictions are 
lifted [35]. For instance, a South Korean economic evaluation 
found that earlier use of biosimilar etanercept was cost- 
Figure 2. Elements of market dynamics to consider in budget impact analysis of a biosimilar.
EXPERT OPINION ON BIOLOGICAL THERAPY 13
effective in the treatment of rheumatoid arthritis following the 
failure of methotrexate therapy [53].
6. Factors influencing cost-effectiveness of biologic 
therapy following patent expiry
As indicated in Figure 3, we believe that several factors may 
influence the cost-effectiveness of biologic therapy following 
patent expiry.
A biosimilar receives marketing authorization based on the 
totality of the evidence, although residual uncertainties related to 
the benefit-risk assessment may remain at this stage (as is the case 
with any medicine), which can be addressed through post- 
marketing pharmacovigilance [54]. This can be illustrated by a UK 
economic evaluation of biosimilar infliximab for Crohn’s disease, 
which explored the impact of a hypothetical difference in the 
immunogenetic profile of reference and biosimilar infliximab on 
cost-effectiveness [55]. The use of biosimilar infliximab was sup-
ported by the base case analysis given that both reference and 
biosimilar infliximab generated 0.803 quality-adjusted life-years 
over a one-year time horizon, but biosimilar infliximab (health- 
care costs of £18,087) was less expensive than reference infliximab 
(£19,176). In the scenario tested in a sensitivity analysis that 50% of 
the patients would develop antibodies to biosimilar infliximab and 
12.4% to reference infliximab, the minimum price reduction for 
biosimilar infliximab to remain the optimal treatment would need 
to be less than the actual price difference between reference and 
biosimilar infliximab. In the meantime, it was shown that this 
scenario is hypothetical, as a reference and biosimilar infliximab 
show an almost perfect cross-immunogenicity [56].
A second factor relates to the switch from a reference biologic to 
its biosimilar. In this respect, it should be noted that interchange-
ability is decided by each individual European Member State and 
that substitution practices vary between European countries. In the 
United States, a biosimilar can be designated interchangeable if it 
meets specific requirements and interchangeable products can be 
substituted in the pharmacy without physician consent [57]. 
Different switching and substitution practices may influence the 
cost-effectiveness (and the budget impact) of biologic therapy, 
especially in the context of the potential occurrence of the nocebo 
effect. This effect is not associated with the products involved, but 
relates to a patient’s negative perception of the switch [58]. 
Therefore, we believe that there is a need for real-world economic 
evaluations that explore the cost and effectiveness implications of 
Figure 3. Factors influencing cost-effectiveness of biologic therapy following patent expiry.
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switching from reference biologic to biosimilar medicines and 
account for a potential nocebo effect.
A market trend that we observe is the development of a second- 
generation reference biologic that has a different administration 
form than the first-generation reference biologic and its biosimilars: 
e.g. subcutaneous forms of reference trastuzumab and rituximab 
next to intravenous biosimilar trastuzumab and rituximab. The 
administration form has implications in terms of, for example, the 
health-care setting in which the biologic is used (hospital versus 
home), biologic preparation and administration resource use, dos-
ing regimen (body-weighted adjusted dose versus fixed dose), use 
in combination with intravenous chemotherapy, health-care pro-
fessional and patient convenience and preferences [59], all of which 
may have an impact on the overall costs and effectiveness of 
biologic therapy [60]. We now see a similar situation with the 
market entry of the subcutaneous form of reference vedolizumab 
for the treatment of inflammatory bowel disease (in response to the 
development of subcutaneous infliximab by Celltrion). To account 
for these implications, we argue that a full economic evaluation 
comparing a second-generation reference biologic and the first- 
generation biosimilar with a different administration form is 
required.
Some manufacturers offer value-added services in addition 
to the reference biologic or its biosimilar. Examples of such 
services that may provide value to payers, providers, physi-
cians, and patients are disease programs that aim to support 
patient adherence, administration service, educational pro-
grams, and therapeutic drug monitoring [3,10,61]. As value- 
added services may influence the costs and effectiveness of 
biologic therapy, we believe that economic evaluation needs 
to assess a reference biologic or a biosimilar in combination 
with its value-added services.
7. Expert opinion
This Expert Opinion article has argued that the cost of biologic 
therapy can be reduced by the market access of biosimilars and 
by price competition with alternative treatments. The resulting 
improvement in the cost-effectiveness of biologic therapy should 
lead to a revision of the reimbursement decision and conditions. 
Budget impact analyses and economic evaluations need to com-
pare all aspects of off-patent reference biologics, biosimilars, and 
new innovative chemical and biologic medicines, as these products 
influence the budget impact and cost-effectiveness of biologic 
therapy.
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